United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Form 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of July, 2016

 

Commission File Number: 001-35892

 

 

 

GW PHARMACEUTICALS PLC

(Translation of registrant’s name into English)

 

 

 

Sovereign House

Vision Park

Histon

Cambridge CB24 9BZ

United Kingdom

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F   x   Form 40-F   ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes   ¨   No   ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes   ¨   No   ¨

 

 

 

  

Other Events

 

On July 18, 2016, GW Pharmaceuticals plc (the “Company”) announced the closing of the previously announced offering on the NASDAQ Global Market by the Company of 2,800,000 American Depositary Shares (“ADSs”) and the full exercise by the underwriters of their option to purchase 420,000 additional ADSs from the Company at a price of $90.00 per ADS, raising gross proceeds of approximately $289.8 million (before deducting underwriting discounts, commissions and offering expenses). The press release attached as Exhibit 99.1 is furnished and incorporated by reference herein.

 

Exhibits

 

99.1 Press Release dated July 18, 2016

 

 

 

 

 

 

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  GW Pharmaceuticals plc
     
  By: /s/ Adam George
  Name: Adam George
  Title: Chief Financial Officer
     
Date: July 18, 2016